NYSE:AORTMedical Equipment
Artivion (AORT) Stock Can Revenue Growth Outrun Fresh Losses?
Artivion stock edged up about 2% into the close, which is a mild reaction to a quarter that pulled investor psychology in opposite directions. Top line momentum was clear, with Q2 revenue of US$125.8m and solid growth in key aortic products, yet the company swung to a quarterly loss with basic earnings per share moving into negative territory. The market seems to be rewarding revenue traction and the fresh AMDS approval more than it is punishing compressed margins and weaker profitability.
Is...